Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial

Michael A Henderson; Bryan H Burmeister; Jill Ainslie; Richard Fisher; Juliana Di Iulio; B Mark Smithers; Angela Hong; Kerwin Shannon; Richard A Scolyer; Scott Carruthers; Brendon J Coventry; Scott Babington; Joao Duprat; Harald J Hoekstra; John F Thompson

Journal article

Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial

Michael A Henderson, Bryan H Burmeister, Jill Ainslie, Richard Fisher, Juliana Di Iulio, B Mark Smithers, Angela Hong, Kerwin Shannon, Richard A Scolyer, Scott Carruthers, Brendon J Coventry, Scott Babington, Joao Duprat, Harald J Hoekstra, John F Thompson

The Lancet Oncology | ELSEVIER SCIENCE INC | Published : 2015

DOI: 10.1016/S1470-2045(15)00187-4

University of Melbourne Researchers

Michael Henderson Author Surgery - St Vincent's Hospital

Richard Fisher Author Mathematics and Statistics

Grants

Awarded by National Health and Medical Research Council of Australia

Funding Acknowledgements

The National Health and Medical Research Council of Australia (project IDs 251732 and 454745), Cancer Council Australia, Melanoma Institute Australia, and the Cancer Council South Australia.